AMSBIO has launched a new range of research grade biosimilars that enable analysis of biological processes without the need to purchase expensive therapeutic-grade biologics.

研究药物的生物学作用或进行概念证明开发的开发需要该药物的来源。通常，很难获得原始的药物级生物治疗药物进行研究，而不是临床应用。因此，生物学化合物几乎与已由政府监管机构批准的医疗批准的参考生物药物（生物仿制药）相同，这是重要的研究工具。

To develop an effective biologic drug, it is important to synthesize a reference antibody. A reference antibody can greatly facilitate the downstream development of a new biologic drug and can help identify critical cell lines, reagents and performance characteristics. AMSBIO's new range of biosimilar antibodies for research use avoid the need to source an expensive therapeutic product and enable fast and inexpensive assay development.

One of the main challenges in analyzing the impact of biosimilars is obtaining a validated positive control for in-situ analysis. For this task - FFPE cytosections of HEK293T cell pellet that over-express targeted proteins are available from AMSBIO. These cells are obtained by transfection of a sequenced verified cDNA clones transfected into HEK293T cells and the expression is verified by western blot and IHC analysis.